Novartis denies problems with swine flu vaccine

October 26, 2009

Swiss pharmaceutical group Novartis on Monday denied that it faced hurdles in gaining regulatory approval in Switzerland for one of its swine flu vaccines because of possible bacterial contamination.

The vaccine, branded as Celtura, is produced by a technique using cell cultures from dog kidneys, allowing more rapid production than by the more classical method using chicken eggs, according to the company.

Citing anonymous sources close to the case, the Swiss daily Tages-Anzeiger reported on Saturday that the Swiss authority overseeing medicines and therapeutical products, Swissmedic, had found in test batches of Celtura.

A spokesman at Swissmedic told AFP that the agency could "neither confirm nor deny" the report.

Swissmedic is due to give its authorisation for the vaccine this week ahead of a mass vaccination campaign against influenza A(H1N1) in Switzerland.

A spokesman for Novartis, Eric Althoff, insisted on Monday that the Celtura vaccine was not contaminated.

"There is no contamination of Celtura, the process is much cleaner than by chicken eggs," he told AFP.

Novartis is hoping for the green light to market the vaccine from Swiss health authorities in the coming days and from the European Union in the next few weeks.

The spokesman insisted that the production process was the same as that which has been used on a seasonal flu vaccine for several years.

About 8,000 people have taken part in clinical trials of A(H1N1) vaccines, he added.

Novartis already markets another swine in Europe under the brand name Focetria, which is based on chicken egg cultures.

(c) 2009 AFP

Related Stories

Recommended for you

Drug for spinal muscular atrophy prompts ethical dilemmas, bioethicists say

December 11, 2017
When the Food and Drug Administration approved the first drug for people with spinal muscular atrophy a year ago, clinicians finally had hope for improving the lives of patients with the rare debilitating muscular disease. ...

FDA's program to speed up drug approval shaved nearly a year off the process

December 7, 2017
Speeding the pace at which potentially lifesaving drugs are brought to market was a rallying cry for Donald Trump as a candidate, and is a stated priority of his Food and Drug Administration commissioner, Dr. Scott Gottlieb. ...

Dangers of commonly prescribed painkillers highlighted in study

December 6, 2017
Commonly prescribed painkillers need to be given for shorter periods of time to reduce the risk of obesity and sleep deprivation, a new study has revealed.

Viagra goes generic: Pfizer to launch own little white pill

December 6, 2017
The little blue pill that's helped millions of men in the bedroom is turning white. Drugmaker Pfizer is launching its own cheaper generic version of Viagra rather than lose most sales when the impotence pill gets its first ...

Surgery-related opioid doses can drop dramatically without affecting patients' pain

December 6, 2017
Some surgeons might be able to prescribe a third of opioid painkiller pills that they currently give patients, and not affect their level of post-surgery pain control, a new study suggests.

Four-fold jump in deaths in opioid-driven hospitalizations

December 4, 2017
People who end up in the hospital due to an opioid-related condition are four times more likely to die now than they were in 2000, according to research led by Harvard Medical School and published in the December issue of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.